-- Zhejiang Huahai Pharmaceutical (SHA:600521) forecasts its attributable profit will rise 30% to 48% to between 387 million yuan and 440 million yuan in the first quarter from 297.4 million yuan in the year-ago period, according to a Wednesday filing with the Shanghai bourse.
The expected rise is attributable to gains from the offloading of a 67% stake in subsidiary Huahai Tianheng (Shanghai) Pharmaceutical Research, the filing said.
Shares rose 2% during morning trading on Wednesday.